NPH Insulin efficacy in diabetes management

Comparison of efficacy of moderater-acting insulin (NPH) manufactured by Ronak Daru (Ronulin ®) with manufactured by Exir (Lansulin®) in reducing fasting blood sugar in patients with type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013040912938N2

Enrollment

196

Registered

2013-05-01

Start date

2012-12-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabete. Diabetes mellitus

Interventions

Intervention 1: Intervention:NPH manufactured by Ronak Daru (Ronulin ®) through FBS=90-130 mg and HbA1c<7 during 3 months. Intervention 2: control: NPH manufactured by Exir (Lansulin®) through target

Treatment - Drugs

Intervention:NPH manufactured by Ronak Daru (Ronulin ®) through FBS=90-130 mg and HbA1c<7 during 3 months.

control: NPH manufactured by Exir (Lansulin®) through target FBS= 90-130 mg/dl and HbA1c<7 during 3 months.

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: inclusion criteria:1- diabetic patients type 2 treated with insulin with or without oral drug. 2-100mg/dl 18 years old*. 5-(BMI=30)kg/m2.*We have enrolled patients with age more than 18 years, according to reference 17, 18, 19, and 20.Age don’t be considered as a confounding factor because study has randomized design. exclusion criteria: 1- microvascular and macrovascular complications. 2- hypoglycemia(BS250mg/dl). 3-pregnancy or Breastfeeding. 4-use of glucocorticoides or any drug that lead hyperglycemia. 5- uncontrolled HTN(BP>180/105). 6- insulin allergy. 7-use of more than 1.4 U/kg/d insulin. 8-Cr>2 mg/dl or LFT>twofold normal range. 9- Patient withdrew from the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Mean of HbA1c. Timepoint: before and after of study. Method of measurement: HPLC assay.	—

Secondary

Measure	Time frame
Dosage of insulin. Timepoint: before and after of study. Method of measurement: unit.;Hyperglycemia. Timepoint: during study. Method of measurement: with laburatory or SMBG.;Hypoglycemia. Timepoint: during study. Method of measurement: with laburatory or SMBG.;Weight change. Timepoint: before and afterof study. Method of measurement: scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr yues Panahi

chemical injery research center

yunespanahi@yahoo.com+98 21 8821 1524

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026